'We are pleased with the progress we are making with our distribution network, our direct customers and various levels of Government,' says
Non-Disclosure Agreement (NDA)
BioCloud has entered into a Non-Disclosure Agreement, with a leading medical sports authority, to share the full scope of BioCloud's patents and research. The purpose of the NDA is to advance various potential sport applications. Such applications include, but are not limited to, dressing rooms and training facilities.
BioCloud European Standards
Kontrol has initiated the CE standards approval process and BioCloud now has the appropriate power supply ratings for European applications, which is an important prerequisite for European sales. As part of the product requirements for each country within the
Distribution Network
Kontrol has recently added a South Korean firm to its growing distribution network and is in discussion with numerous interested parties.
Kontrol is in the process of establishing a viral/pathogen advisory committee that will work with management to accelerate various BioCloud applications. Kontrol seeks to establish the committee in
Corporate Name Change
Kontrol's corporate name change to
About Kontrol BioCloudTM
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others. Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com
BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.
About
Contact:
Chief Executive Officer
Tel: 905.766.0400
Forward-Looking Statements
This news release contains 'forward-looking information' within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as 'may', 'will', 'expect', 'likely', 'should', 'would', 'plan', 'anticipate', 'intend', 'potential', 'proposed', 'estimate', 'believe' or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions 'may' or 'will' happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company's product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of BioCloud are subject to the risk that BioCloud may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol's lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
(C) 2021 Electronic News Publishing, source